SpyGlass Pharma, Inc. Common Stock (SGP)
SGP Stock Price Chart
Explore SpyGlass Pharma, Inc. Common Stock interactive price chart. Choose custom timeframes to analyze SGP price movements and trends.
SGP Company Profile
Discover essential business fundamentals and corporate details for SpyGlass Pharma, Inc. Common Stock (SGP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Jan 2008
Employees
1.49k
Website
http://www.spyglasspharma.comCEO
Patrick H. Mooney
Description
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
SGP Financial Timeline
Browse a chronological timeline of SpyGlass Pharma, Inc. Common Stock corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 2 Sept 2026
EPS estimate is -$0.52.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.51.
Earnings released on 14 May 2026
EPS came in at -$0.69 falling short of the estimated -$0.50 by -37.15%.
Earnings released on 26 Mar 2026
EPS came in at -$5.72 falling short of the estimated -$0.57 by -896.13%.
SGP Stock Performance
Access detailed SGP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
